Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

TROP2-Targeting Antibody-Drug Conjugates

November 10th 2023

The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.

Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies

November 10th 2023

A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.

French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC

November 9th 2023

Dr Gligorov underscores the significance of real-world data in France supporting the effectiveness of tucatinib and trastuzumab in combination for patients with heavily pretreated HER2+ metastatic breast cancer, with notable benefits even in cases with brain metastasis.

Treatment Sequencing Approaches for Patients With HER2+ mBC

November 9th 2023

Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.

Reviewing Best Practices in the Surgical Management of Breast Cancer: How Disease Stage Informs Treatment

November 7th 2023

In this first episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, explain how treatment approaches differ based on disease stage in patients with breast cancer.

FDA Awards Orphan Drug Designation to Rhenium Obisbemeda in Breast Cancer With Leptomeningeal Metastases

November 3rd 2023

The FDA has granted an orphan drug designation to rhenium obisbemeda as a potential therapeutic option for patients with breast cancer and leptomeningeal metastases.

Novel Therapies Under Investigation for HER2+ mBC

November 3rd 2023

Jane Meisel, MD, shares enthusiasm about upcoming trials and therapies in HER2+ metastatic breast cancer, with new antibody-drug conjugates showing promise.

Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

November 3rd 2023

Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.

Managing T-DXd Toxicities in Gastric Cancer

November 3rd 2023

Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.

Gastric Cancer Treatment: T-DXd

November 3rd 2023

A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.

Global Perspectives: Evolution of Advanced HER2+ Breast Cancer Treatment

November 2nd 2023

Joseph Gligorov, MD, reviews advances in the treatment of advanced HER2+ breast cancer, shares his global perspective, and explains how ESMO and NCCN guidelines are similar.

Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)

November 2nd 2023

Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.

FDA Lifts Clinical Hold on Phase 1 Trial Evaluating XMT-2056 in HER2-Expressing Solid Tumors

October 31st 2023

The FDA has lifted the clinical hold placed on a phase 1 trial evaluating XMT-2056 monotherapy in patients with HER2-high or -low advanced or recurrent solid tumors.

Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial

October 30th 2023

Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.

Dr Tarantino on Understanding the Role of ADC Payloads in Breast Cancer

October 27th 2023

Paolo Tarantino, MD, discusses the importance of understanding the role that payloads play in treatment with antibody-drug conjugates in breast cancer.

MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast Cancer

October 27th 2023

Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.

Adverse Events Seen With Second- and Third-Line Therapies in Patients With HER2+ mBC

October 27th 2023

Jane Meisel, MD, discusses managing adverse events in patients receiving second- or third-line treatments for HER2+ metastatic breast cancer, emphasizing close monitoring, patient communication, and symptom-specific interventions.

Clinical Trial Data and Real-World Evidence on Therapy Sequencing for HER2+ mBC

October 27th 2023

Jane Meisel, MD, emphasizes the growing role of real-world evidence in guiding therapy sequencing for HER2+ metastatic breast cancer due to rapidly evolving treatment standards.

Management of ADC Toxicities in Lung Cancer

October 27th 2023

A nurse practitioner provides insights on toxicity management strategies for patients with lung cancer who are receiving antibody-drug conjugates.

Antibody-Drug Conjugates in Lung Cancer

October 27th 2023

A medical oncologist reviews the antibody-drug conjugate landscape in lung cancer.